Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Cancer. 2012 Dec 1;131(11):2471-7. doi: 10.1002/ijc.27632. Epub 2012 Jun 7.

Targeted therapy for triple-negative breast cancer: where are we?

Author information

1
UCD Clinical Research Centre, St. Vincent's University Hospital, Dublin, Ireland. michael.j.duffy@ucd.ie

Abstract

Breast cancers that are negative for estrogen receptor (ER), progesterone receptors (PR) and HER2, using standard clinical assays, have been dubbed triple-negative (TN). Unlike other molecular subtypes of invasive breast cancer, validated targeted therapies are currently unavailable for patients with TN breast cancer. Preclinical studies however, have identified several potential targets such as epidermal growth factor receptor (EGFR), SRC, MET and poly ADP ribose polymerase 1/2 (PARP1/2). Because of tumor heterogeneity, it is unlikely that any single targeted therapy will be efficacious in all patients with TN breast cancer. The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy.

PMID:
22581656
DOI:
10.1002/ijc.27632
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center